Financials

Company Profile

November 26, Inc., formerly BIOLASE, Inc., is not engaged in any business activities. The Company has no assets.

Employees

157

Sector

Date	Price	Change	Volume
21/09/26	USD 0.000000	-	6
17/09/26	USD 0.000000	-100.00%	2

Delayed Quote OTC Markets

Market Closed - OTC Markets 11:30:05 15/09/26 pm AEST			5-day change	1st Jan Change
0.000001 ^USD	0.00%		0.00%	-

27/08/25	MegaGen Implant Co., Ltd. acquired All Assets of BIOLASE, Inc from BIOLASE, Inc. (OTCPK:BIOL.Q).	CI
19/05/25	EnVVeno Medical Names Jennifer Bright CFO	MT

27/08/25	MegaGen Implant Co., Ltd. acquired All Assets of BIOLASE, Inc from BIOLASE, Inc. (OTCPK:BIOL.Q).	CI
19/05/25	EnVVeno Medical Names Jennifer Bright CFO	MT
05/03/25	Motion for Asset Sale Approved for BIOLASE, Inc.	CI
25/02/25	Second Amended Combined Liquidation Plan & Disclosure Approved for BIOLASE, Inc.	CI
21/02/25	Second Amended Combined Liquidation Plan & Disclosure Statement Filed by BIOLASE, Inc.	CI
18/02/25	Motion for Exclusivity Period Extension Approved For BIOLASE, Inc.	CI
14/02/25	Motion for Asset Sale Filed by BIOLASE, Inc.	CI
29/01/25	First Motion for Exclusivity Period Extension Filed by BIOLASE, Inc.	CI
14/01/25	First Amended Disclosure Statement Approved on Interim Basis for BIOLASE, Inc.	CI
13/01/25	First Amended Combined Liquidation Plan and Disclosure Statement Filed by BIOLASE, Inc.	CI
08/01/25	Disclosure Statement Conditionally Approved for BIOLASE, Inc.	CI
23/12/24	Combined Liquidation Plan and Disclosure Statement Filed by BIOLASE, Inc.	CI
15/11/24	Motion for Asset Sale Approved for BIOLASE, Inc.	CI

01/04/24	Ascendiant Capital Adjusts Biolase's Price Target to $4 From $15, Reiterates Buy Rating	MT
31/05/23	Lake Street Adjusts Price Target on Biolase to $0.40 From $1.50, Maintains Buy Rating	MT
21/01/23	Lake Street Assumes Biolase at Buy With $1.50 Price Target	MT
21/05/22	Lake Street Initiates Biolase at Buy, Sets Price Target at $12	MT

15/10/25	BIOLASE Showcases Breakthrough YSGG Laser Protocol for Predictable Periodontitis Treatment at AAP 2025	PR
08/11/24	Biolase: Q3 Earnings Snapshot	AQ
08/11/24	BIOLASE : Quarterly Report for Quarter Ending September 30, 2024 (Form 10-Q)	PU
02/10/24	BIOLASE : Voluntarily Initiates Chapter 11 Proceedings Form 8 K	PU
09/08/24	Biolase: Q2 Earnings Snapshot	AQ

Manager	Title	Age	Since
Gwang-Bum Park CEO	Chief Executive Officer	65	10/09/2025
Steven Sandor COO	Chief Operating Officer	46	06/07/2022
Samuel B. Low CTO	Chief Tech/Sci/R&D Officer	-	01/10/2016

Director	Title	Age	Since
Jonathan Lord CHM	Chairman	71	01/09/2017
Kathleen O'Loughlin BRD	Director/Board Member	75	16/08/2021
Martha Somerman BRD	Director/Board Member	-	16/08/2021

Date	Insider	Type	Main position	Quantity	% Market Cap.
28/9/23	Goldman Sachs & Co. LLC (Private Banking)	Other	Company	144,501	13.8444%
8/6/23	Jonathan Lord	Free	Chairman	721,154	2.3039%
8/6/23	Kathleen O'Loughlin	Free	Director	502,404	1.6050%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
BIOLASE, INC.	0.00%	0.00%	-	-	36
CHURCHILL CAPITAL CORP XI	+1.64%	-3.64%	-	-	692M
DRUGS MADE IN AMERICA ACQUISITION II CORP.	+0.10%	-0.10%	-	-	647M
BAIN CAPITAL GSS INVESTMENT CORP.	+0.19%	+0.19%	-	-	602M
CHURCHILL CAPITAL CORP XII	+0.65%	+1.36%	-	-	599M
CANTOR EQUITY PARTNERS IV, INC.	+0.15%	-0.39%	+1.28%	-	589M
CENTIEL AG	+0.68%	-6.29%	+279.62%	-73.63%	587M
AMERICAN EXCEPTIONALISM ACQUISITION CORP. A	-0.27%	+0.45%	+11.60%	-	552M
NEW AMERICA ACQUISITION I CORP.	0.00%	-0.10%	-	-	501M
Average	+0.35%	-0.95%	+97.50%	-73.63%	530M
Weighted average by Cap.	+0.43%	-1.13%	+99.13%	-73.63%